Lenacapavir is back in headlines as a long-acting HIV prevention shot rolling out in Africa and beyond, amid funding and access fights.
The US is ending its global health supply program, risking shortages of HIV and malaria medicines in Africa and Haiti. The transition to new procurement methods is uncertain, with potential gaps in life-saving supplies amid ongoing aid reductions and policy shifts.
UNAids warns that funding cuts and tightening civic space threaten progress against HIV. Six-month lenacapavir injections are rolling out in South Africa, with early results showing promise but concerns over access and equity persist as external aid declines.